GH Increase2-3x
Studies8
Participants1,286
StatusAvailable
Ipamorelin
Selective Growth Hormone Secretagogue (GHRP)
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that specifically stimulates the release of growth hormone without affecting other hormones. Unlike other GHRPs, Ipamorelin does not increase cortisol, acetylcholine, prolactin, or aldosterone levels, making it the most selective and well-tolerated growth hormone secretagogue available for research and therapeutic applications.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
8.7%
injection site reaction
12.3%
mild water retention
5.8%
transient fatigue
4.2%
mild headache
3.6%
joint stiffness
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
Ipamorelin is currently in research phase and is not FDA-approved for human therapeutic use. This information is for educational purposes only and should not replace consultation with healthcare providers. Individual results may vary. Medical supervision is recommended for all research applications.